• Bosentan reduces immobility time in the forced swimming test and tail suspension test.
Introduction
Endothelins were first described as 21-amino acids peptides derived from endothelial cells with potent vasoactive properties [1] . In mammals, the endothelin family comprises 3 ligands (ET-1, ET-2 and ET-3) and 2 endothelin-receptors (endothelin ET A and ET B ) [2] [3] [4] . Immune cells such as macrophages [5] , monocytes and lymphocytes [6] produce endothelin and also express endothelin receptors, indicating the autocrine effect of endothelin in those cells, which is related to modulation of cytokine production [7] [8] [9] .
Cytokines are cellular mediators that drive innate and adaptive immune responses to various stimuli. The ability of nervous tissue to respond to cytokines allows immediate and complex adaptive peripheral [10, 11] and central [12] responses of the organism. Interleukin (IL)-1␤, IL-6 and tumor necrosis factor (TNF)-␣ are pro-inflammatory cytokines that have been related to the pathophysiology of depression. The IL-1␤ and TNF-␣ can induce depressive-like symptoms in animal models of helplessness (or despair) like Porsolt's forced swimming test (FST) [13, 14] . In contrast, the systemic administration of IL-6 induces antidepressant activity in FST, stimulates the hypothalamo-pituitary-adrenocortical (HPA) axis, and increases tryptophan levels and serotonin metabolism in several brain regions [15] . Moreover, the modulation of circulating levels of these cytokines has proved to be necessary to reverse depressive-like symptoms by antidepressants such as imipramine, venlafaxine and Hypericum perforatum [16] [17] [18] .
Endothelin receptor antagonists inhibit the production of cytokines during inflammation [7] [8] [9] . Therefore, we reason that targeting endothelin receptors could affect depressive-like behavior by modulating the production of cytokines. In this sense, the effects of bosentan, a mixed endothelin ET A /ET B receptor antagonist, was investigated in FST, tail suspension test (TST) and elevated plus maze test (EPM). Moreover, we also investigated the effects of bosentan on circulating levels of IL-6 after exposure to FST. Bosentan was selected since it was the endothelin receptor antagonist prototype and the first to enter clinical use [19] .
Materials and methods

Animals
Male Swiss mice of 20-25 g from Universidade Estadual de Londrina were used in this study. Mice were maintained at the Department of General Psychology and Behavior Analysis of the same University, at least two days before the experiments with free access to water and food, and temperature of 23 • C ± 2. A 12/12 h light/dark cycle was used with lights on at 6 and off at 18 h. All behavioral tests were made between 12-17 h. Animal care and handling procedures were approved by Ethics Committee of the Universidade Estadual de Londrina (OF. CIRC. CEUA N • 07/2011). Every effort was made to minimize the number of animals used and their suffering.
Protocol of treatment
Bosentan (a mixed endothelin ET A /ET B receptor antagonist, diluted in 1% solution of xanthan gum in saline) was administered per orally (p.o.) with the aid of a gavage needle at the doses of 0.3-300 mg/kg, 1 h before FST or at the dose of 3 mg/kg 1 h before EPM and TST. The vehicle group received solution of xanthan gum 1% in saline (p.o.), 1 h before the tests. Nortriptyline (15 mg/kg, i.p., 1 h) was used as control drug. All groups were of 10 mice.
Forced swimming test
FST was performed as previously described [20] . Briefly, mice were placed into a cylinder of 10 cm diameter and 30 cm height with water at 25 • C ± 1 reaching 19 cm of water column to avoid the tail touch in bottom [20] . Sessions were recorded and the immobility time (depression-like behavior) was registered in seconds by an experimenter unaware of the groups. Immobility was considered when the animal moved just to keep his head out of the water in the last 4 min of the total swimming session of 6 min.
Tail suspension test
The TST was used as described before [21] to corroborate the antidepressant activity of treatment with bosentan. Mice received bosentan (3 mg/kg, p.o.), vehicle or nortriptyline (15 mg/kg, i.p.), 1 h before the TST. A short piece of adhesive tape was used to attach mice by the tail about 20 cm above the floor. Mice were recorded during 6 min and the immobility time (depression-like behavior) was registered in seconds by an experimenter unaware of the groups.
Elevated plus maze
In order to discard possible anxiogenic or anxiolytic activity of bosentan, which in turn would also modulate the immobility time in forced swimming test [22] , the EPM test was used as described before [23] . Mice received bosentan (3 mg/kg, p.o.), vehicle or nortriptyline (15 mg/kg, i.p.), 1 h before the EPM test. The number of entries and the time spent in the open and the enclosed arms were recorded during the session of 5 min.
Cytokine measurement
Mice were treated with bosentan (0.3-300 mg/kg, p.o.), vehicle or nortriptyline (15 mg/kg, i.p.), 1 h before FST. In the sham group, the cytokine levels on blood samples were determined 6 min after swimming for just 3 s. At the end of the test, mice were terminally anaesthetized with 1.5% isoflurane (Abbott Park, IL, USA) and the blood samples were collected in microcentrifuge tubes. The samples were centrifuged at 1300 rcf for 20 min and the supernatant collected. IL-6 levels were determined by ELISA using eBioscience kits as indicated by manufacturer. The results are expressed as picograms (pg) of IL-6 per ml of serum (n = 10).
Statistical analysis
Since the variables were only the treatments, we used analysis of variance with one criterion (One-way ANOVA) followed by the multiple comparison Tukey's test. Differences were considered significant for P < 0.05.
Results
Treatment with bosentan reduces depression-like behavior in FST and TST
Treatment with bosentan showed significant reduction of the immobility time in the FST in a dose-dependent manner (Fig. 1A) . A bell shaped curve was observed with no antidepressant-like activity at the dose of 0.3 mg/kg of bosentan, maximal effect with the dose of 3 mg/kg and reduction of effect with the dose of 30 mg/kg up to no effect with the dose of 300 mg/kg of bosentan. Therefore, the dose of 3 mg/kg was selected for the next experiments at Fig. 1B -D. Treatment with bosentan significantly reduced the immobility time in TST (Fig. 1B) , but showed no significant difference in the percentage of entries into the open arms (Fig. 1C) or in the time spent in the open arms (Fig. 1D) , neither in entries into the closed arms in EPM (data not shown) test. Taken together, these data suggest that bosentan reduced immobility time in FST due to an antidepressant-like activity, exclusively. The control drug nortriptyline at a dose selected from the literature [24] presented antidepressant-like activity as expected (Fig. 1A and B) . Curiously, the treatment with nortriptyline showed an acute anxiolytic activity in EPM test by increasing both the percentage of entries into and time spent in the open arms (Fig. 1C and D) .
Treatment with bosentan increases IL-6 serum levels in mice exposed to FST
Exposure to FST did not alter the serum levels of IL-6 (Fig. 2) . However, the treatment with bosentan increased IL-6 serum levels (Fig. 2) . Again, a bell shaped curve was observed with significant increase in IL-6 serum levels in the groups treated with bosentan at the doses of 3 and 30 mg/kg, as well as nortriptyline group. The doses of bosentan of 0.3 and 300 mg/kg, or vehicle did not alter significantly the serum levels of IL-6 (Fig. 2) .
Discussion
The Porsolt's forced swimming test (FST) is the most widely used test for assessing pharmacological antidepressant activity of compounds [20] . In the present study, we used FST to investigate a new therapeutic approach for treatment of depressive disorders by antagonizing endothelin receptors with bosentan.
Depressive disorders have been associated with serotonergic and catecholaminergic neurotransmission, but also with disturbances of systemic and brain levels of cytokines [7, 13, 25, 26] . Despite the fact that higher levels of circulating IL-6 were found in patients with major depressive disorder [25] , several antidepressant treatments induce acute increase of IL-6 in the central nervous system and in the blood [17] . This evidence suggests that increased levels of IL-6 are associated with antidepressant action of drugs. In agreement, nortriptyline, a tricyclic antidepressant whose mechanism of action relies on increase of serotonergic and noradrenergic neurotransmission [27] , induced an increase of systemic IL-6 levels at a dose with antidepressant-like activity. To our knowledge, this is the first reported association between antidepressant action and IL-6 increases due to nortriptyline treatment. This finding can be seen as suggestive that increases in systemic Fig. 2 . Effects of bosentan and nortriptyline on circulating IL-6 levels after forced swimming test. Mice were treated with bosentan (0.3-300 mg/kg, p.o.), vehicle or nortriptyline (15 mg/kg, i.p.) 1 h before the test. Blood samples were collected immediately after the forced swimming test session and the IL-6 serum levels were determined by ELISA. Data represent the mean ± S.E.M. serum concentration of 10 mice per group. *P < 0.01 compared to sham group and P < 0.05 compared to vehicle group, **P < 0.001 compared to sham group and P < 0.01 compared to vehicle group, # P < 0.05 compared to all other groups (One-way ANOVA followed by Tukey's test).
IL-6 level could account for the antidepressant effect of nortriptyline. Importantly, bosentan also increased the systemic IL-6 levels at the doses with antidepressant-like effect in the FST and TST. Of note, bosentan inhibits inflammation and inflammatory pain at the dose of 100 mg/kg in experimental animals, but not at 3 mg/kg [9, 28, 29] . Therefore, it is likely that the antidepressant-like and anti-inflammatory/analgesic actions of bosentan are dissociated. In fact, the antidepressant-like effect of bosentan was associated with increased IL-6 blood levels as for nortriptyline, which would, eventually, result in increased inflammation. On the other hand, bosentan at 100 mg/kg reduces inflammation and pain by reducing the production of inflammatory cytokines including TNF-␣ and IL-1␤ [30] . Thus, it is reasonable that low doses of bosentan present antidepressant-like activity by increasing IL-6 levels while it inhibits inflammation at higher doses by reducing cytokine production, which is compatible with the bell shape curve observed in this study.
Furthermore, the present data does not exclude the participation of serotonin and noradrenaline in the antidepressant effect of nortriptyline, but rather suggests an additional mechanism of action that could, in fact, be tightly related to serotonin and noradrenaline neurotransmission as previously described in adipocytes [31] . In a systemic approach, for example, adrenal glands seem to be an important source of circulating IL-6 since adrenalectomy attenuates the stress-induced increase in levels of this cytokine [32] . On the other hand, IL-6-induced antidepressantlike behavior showed to be related to enhanced activity of adrenal via HPA axis [15] as a positive feedback that maintains this adaptive response to stress. In this line, ET-1 can inhibit adrenal gland activity [33] , which also suggests a possible mechanism to explain the modulator effect of bosentan on circulating IL-6 levels observed in this work. Considering another pathway, antidepressants such as imipramine can inhibit splanchnic nerve activation [34] which, in turn, modulates the activity of adrenal gland [35] . Together, these two convergent pathways could also explain the increased levels of circulating IL-6 induced both by the treatment with nortriptyline and bosentan.
Many cell types and tissues can be important sources of circulating IL-6, and how much this relationship of serotonin/ noradrenaline and IL-6 is important in the case of bosentan is unknown. In fact, there is limited direct evidence on the mechanisms by which bosentan or blocking ET A and ET B receptors could induce an increased of IL-6 blood levels. Nevertheless, four additional points might help to give an insight to understand a complex network resulting in increased IL-6 production by ET-1 modulation. First, a decrease of ET-1 levels or expression occurred concomitantly with increase of IL-6 levels in some models of inflammation [36, 37] . Second, ET-1 via ET A and ET B receptors induces an increase of IL-6 production in a synergic manner with 8-Br-cAMP, noradrenaline and adrenaline in adipocytes. This synergy was selective to IL-6 since ET-1-induced TNF␣ and IL-1␤ production was inhibited by 8-Br-cAMP (mimicking the intracellular signaling of noradrenaline and adrenaline). Furthermore, this synergy occurs at low levels of ET-1 as expected for synergic processes [31] . In this sense, ET-1 synergizes with other cytokines such as IL-1␤ to induce IL-6 production [38] . Third, treatment with bosentan increases the circulating ET-1 levels by 2 fold in humans and 2-30 folds depending on the animal specie by a mechanism possibly related to blockade of endothelial ET B receptors, which have a role in the clearance of circulating ET-1 [39] . Taking into account these three points, it is possible that in the present experimental condition, the pretreatment with bosentan increased the circulating levels of ET-1 at optimal doses, e.g. doses not too high to block all receptors and not too low to show no effect on circulating ET-1 levels. The increased levels of ET-1 without blockade of all receptors (intermediary doses) together with the initial release of catecholamines in the FST test propitiated optimal serum levels of ET-1 and catecholamines to induce an increase in circulating IL-6 levels and as a result, anti-depressive-like behavior. The forth point is that depending on the ET-1 levels, ET A and ET B receptors may present complementary or even opposing roles. For instance, ET-1 induces ET B -dependent analgesia and ET A -dependent hyperalgesia at high doses while at low doses, ET-1 induces ET A and ET B -dependent hyperalgesia [40] [41] [42] . Therefore, the effects of ET-1 might depend on its levels.
Conclusion
We reported for the first time that bosentan, a mixed endothelin ET A /ET B receptor antagonist, induces antidepressant-like activity associated with elevation of circulating IL-6 levels. Therefore, the present data unveil a previously unrecognized participation of endothelin in depression and suggests a possible mechanism of action.
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